Michael Kelly

Michael Anthony Kelly is the founder of Sentry Hill Partners LLC, founded in 2018, where the title held is President.
Current jobs include Independent Director at DMC Global, Inc. since 2020; Lead Independent Director at NeoGenomics, Inc. since 2020; Director at NeoGenomics Laboratories, Inc. since 2020; Independent Director at Prime Medicine, Inc. since 2021; and Director at Chroma Medicine, Inc. since 2023.
Former jobs include Director at Direct Relief; Independent Director at HOOKIPA Pharma, Inc. from 2019 to 2023; Independent Director at Aprea Therapeutics, Inc. from 2020 to 2022; Director at Hookipa Biotech AG from 2019 to 2024; Independent Director at Amicus Therapeutics, Inc. from 2020 to 2026; Senior Vice President-Global Business Services at Amgen, Inc. from 2014 to 2017; Vice President-Finance & Controller at Biogen, Inc. from 1998 to 2000; Chief Financial Officer at Tanox, Inc. from 2000 to 2003; Principal at Onyx Capital Management LLC; Chief Financial Officer & Vice President at The NutraSweet Co. from 1996 to 1998; Chief Financial Officer at Monsanto Life Sciences Co.; and Chief Financial Officer & Vice President-Finance at Nutrasweet Kelco Co. Ltd. from 1996 to 1998.
Education includes undergraduate studies at Florida A&M University.